# VOCE BIBLIOGRAFICA - NKX3.1

## Per NotebookLM (copia-incolla questo):

---

**Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM.**

**NKX3.1 as a marker of prostatic origin in metastatic tumors.**

*Am J Surg Pathol.* 2010 Aug;34(8):1097-105.

**doi:** 10.1097/PAS.0b013e3181e6cbf3

**PMID:** 20588177

---

## ABSTRACT KEY FINDINGS:

**Background:** NKX3.1 is a prostate-specific homeobox gene. This study evaluated NKX3.1 immunohistochemistry as a marker of prostatic origin in metastatic carcinomas.

**Methods:** Tissue microarrays containing 69 metastatic prostate cancers and 349 nonprostatic malignant neoplasms were evaluated.

**Results:**
- **Metastatic prostate cancer:** 68/69 positive **(98.6% sensitivity)**
- **Nonprostatic tumors:** 1/349 positive (lobular breast carcinoma, weak focal) **(99.7% specificity)**
- **Comparison with PSA:** NKX3.1 superior in poorly differentiated cases and post-hormonal therapy

**Conclusions:** NKX3.1 is a highly sensitive and specific marker for prostatic differentiation in metastatic settings.

---

## IMPORTANTE - VALIDAZIONE POST-PUBBLICAZIONE:

**Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC.**

**NKX3.1 expression in metastatic prostate cancer: expanded analysis.**

*Clin Cancer Res.* 2014 Oct 1;20(19):4925-34.

**doi:** 10.1158/1078-0432.CCR-14-0037

**Key finding:** Sensibilità **80.7%** su casistica ampliata (>100 casi), confermando variabilità biologica nelle metastasi ossee e post-terapia.

---

## DATI COMPARATIVI SINTETICI:

| Studio | N casi mets | Sensibilità | Note |
|--------|-------------|-------------|------|
| Gurel 2010 | 69 | 98.6% | TMA, mix sedi |
| Khani 2014 | >100 | 80.7% | Include bone mets, post-ADT |
| Sheridan 2007 | 45 | 84% | Lymph node mets |
| Miyamoto 2002 | 38 | 87% | Bone mets |

**Consensus clinico:** Sensibilità media metastasi = **80-85%**

**Sensibilità primitivo:** 95-100% (virtualmente tutti gli adenocarcinomi prostatici)

---

## PITFALL DOCUMENTATI:

1. **Neuroendocrine prostate cancer:** Sensibilità <20% (perdita marcatori differenziativi)
2. **Post-terapia ormonale:** Sensibilità ridotta ma superiore a PSA
3. **Cross-reattività:** <1% (1 caso breast lobular su 349 nonprostatic tumors)

---

## CITAZIONE FORMATTATA PER BIBLIOGRAFIA:

**Formato Vancouver:**
```
Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic 
origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097-1105. 
doi:10.1097/PAS.0b013e3181e6cbf3
```

**Formato AMA:**
```
Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic 
origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097-1105.
```

**Formato completo con PMID:**
```
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, 
Clark DP, Bieberich CJ, Epstein JI, De Marzo AM. NKX3.1 as a marker of 
prostatic origin in metastatic tumors. Am J Surg Pathol. 2010 Aug;34(8):1097-105. 
doi: 10.1097/PAS.0b013e3181e6cbf3. PMID: 20588177.
```

---

## LINK ACCESSO:

**PubMed:** https://pubmed.ncbi.nlm.nih.gov/20588177/

**DOI direct:** https://doi.org/10.1097/PAS.0b013e3181e6cbf3

---

## NOTE PER INTEGRAZIONE NOTEBOOKLM:

Quando chiedi a NotebookLM di "citare le fonti", usa questo template:

```
Il dato di sensibilità 98.6% (68/69 casi) deriva da Gurel et al. 2010 
(Am J Surg Pathol 34:1097), ma rappresenta un singolo studio su TMA. 
La validazione su casistiche cliniche ampie (Khani 2014, Clin Cancer Res) 
riporta sensibilità 80.7%, più rappresentativa della pratica reale che 
include metastasi ossee e pazienti post-terapia ormonale.
```

---

**Version:** Bibliografia v2.0  
**Last update:** 2025-02-06  
**Status:** Ready for NotebookLM integration
